2023 Fourth Quarter and Full Year Conference Call

February 20, 2024 • 4:30 PM ET

Feb 20, 2024 • 4:05 PM EST

FY 2023 Year End Results

Fiscal Year Ended Dec 31, 2023

Total YoY revenue increased 12%

Q4’23 Adj. EBITDA increased 900% to $9M

Total Full Year revenue increased 16%

Full year Adj. EBITDA increased 107% to $3M

Company Profile

NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma
Services Division serves pharmaceutical clients in clinical trials and drug development.

Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad and San Diego, California; Research Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and Phoenix, Arizona; and CAP accredited laboratories in Cambridge, United Kingdom; Rolle, Switzerland; and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia. 

Latest 10-K

View Latest 10-K

NeoGenomics, Inc.

Nasdaq: NEO

Market/Symbol

Price

Change

Volume

Day Range

52 week Range

IR Contact Information

Investor Relations Jeffrey Sherman
Chief Financial Officer
T: 239.768.0600 x2726
jeff.sherman@neogenomics.com

Transfer Agent Broadridge Shareholder Services
1155 Long Island Avenue
Edgewood, NY 11717-8309
T: (888) 789-8606